The webinar of ARM’s 2021 Cell & Gene State of the Industry Briefing – which took place Wednesday, January 13 – is now available below. This event is a top-level gathering for key stakeholders in the field and includes ARM’s annual yearly update on the sector’s progress followed by a panel session featuring top CEOs and executives highlighting future inflection points for cell and gene therapies in the coming year.
Janet Lambert, CEO, Alliance for Regenerative Medicine
Terry-Ann Burrell, Chief Financial Officer, Beam Therapeutics (moderator)
Marianne De Backer, Member of Executive Committee and EVP, Head of Strategy and Business Development & Licensing, Pharmaceuticals Division, Bayer
Sandy Macrae, President & CEO, Sangamo Therapeutics
Ken Mills, CEO, REGENXBIO
Adrian Rawcliffe, CEO, Adaptimmune
Over 800 of the cell and gene therapy field’s top stakeholders watched the session live in 2021 including company founders, C-level business executives, investors, media, patient advocates and academic leaders interested in learning more on the sector’s recent advances and outlook for the industry in the coming year.
